About Linda Bunschoten - Chief Marketing Officer

Linda has 25+ years of experience uncovering pain points and strategizing with companies in the healthcare industry in order to secure and retain more clients. Her chief thinking responsibilities include translating insight into strategy and ensure that all MarCom and Product Management activities contribute to our overall customer experience and meet our industry’s quality expectations.
Aug 2020

Risk-based Monitoring Software Key Players Influencing the Market

By |2020-09-22T08:55:47+00:00August 26, 2020|News|0 Comments

The report provides key statistics on the market status of the leading Risk-based Monitoring (RBM) Software market players and offers key trends and opportunities in the market.

May 2020

Machine Learning-Based Predictions for All Clinical Research Metrics

By |2020-09-29T05:36:15+00:00May 27, 2020|Neat Features, News|0 Comments

MyRBQM® Portal's new Machine Learning predictive analytics model is far less sensitive to noise, it better generalizes data, and provides narrower CIs in long time series. Singular Spectrum Analysis is particularly valuable for long time series, as mostly observed in clinical trials.

Mar 2020

Cyntegrity Amongst Companies Fighting Back the COVID-19 Outbreak

By |2020-03-23T13:48:08+00:00March 23, 2020|News|0 Comments

Frontiers Health Ecosystem Companies Fighting Back the COVID-19 Outbreak As the COVID-19 outbreak continues, it has become even more challenging for patients to seek in- person medical care and for healthcare providers (HCP) to guarantee community health services for people who may have symptoms [...]

Mar 2020

Coronavirus | COVID-19 RACT Now Available

By |2020-09-23T11:14:53+00:00March 20, 2020|Neat Features, News, RBQM Product Updates|0 Comments

Cyntegrity developed a special COVID-19 RACT that guides those involved in clinical trials on specific risks which may arise as a result of COVID-19, and how they can mitigate them. This special RACT is part of the COVID-19 rapid deployment pack for ad-hoc centralized monitoring.

Feb 2020

Indication Focused RBQM for Rare Disease Drug Development

By |2020-02-28T08:30:17+00:00February 28, 2020|Blog|0 Comments

Adaptive and intelligent Risk Based Quality Management (RBQM) is a powerful strategy for rare disease research. One of the main benefits is that RBQM allows for patient-centric trial design that is uniquely tailored to the specific rare disease.

Feb 2020

Healthy Volunteers – Phase 1 RACT Now Available

By |2020-09-23T11:16:28+00:00February 11, 2020|Neat Features, News, RBQM Product Updates|0 Comments

The need for a controlled research environment adds another risk dimension to the Phase 1 study design. The new Healthy Volunteers - Phase 1 RACT serves as a helpful source to ensure maximum subject safety and a reliable outcome.

Upcoming Events

Register Today!

Get Free Test Access
Go to Top